Impacts of Cash Transfers on Child Neurodevelopment (Auxilio Brasil)
Launched by NEW YORK STATE PSYCHIATRIC INSTITUTE · Jul 26, 2022
Trial Information
Current as of June 27, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, called "Impacts of Cash Transfers on Child Neurodevelopment," is looking at how a cash assistance program in Brazil, called Auxilio Brasil (AB), can affect the development and mental health of children from families who may not have many resources. The study will involve 300 families who are already receiving AB. These families will be randomly divided into two groups, with one group receiving a higher cash transfer of $40 per month and the other group receiving a lower amount of $2 per month for two years. The focus is on children aged 7 to 10 years old, and researchers will assess how these different amounts of financial support impact children's experiences of stress and their overall development.
To participate in the study, mothers need to be between 23 and 45 years old, receiving AB cash transfers, and have at least one child between the ages of 7 and 10 living with them. The children must also be in that age range and have a certain level of intelligence, but having common developmental disorders like ADHD won't disqualify them. Throughout the study, researchers will check in with families at different times to see how the cash transfers affect the children's health and growth. This trial hopes to find out if more financial support leads to better outcomes for children and whether the effects last after the study is over.
Gender
ALL
Eligibility criteria
- Mother:
- Inclusion Criteria:
- • 1. Age 23-45 years old
- • 2. Receiving AB cash transfers
- • 3. Has at least two or more children ages 7- 10 years old at time of recruitment (up to 4 children per family)
- • 4. Able to consent
- Exclusion Criteria:
- • 1. Mother and child do not reside in same household
- Child:
- • Inclusion Criterion
- • 1. Age 7-10 years old
- • 2. Intellectual Disability
- • Exclusion Criterion
- • 1. Does not reside in same household as the mother
- • 2. Major Axis I disorder (e.g., Autism, Schizophrenia, Bipolar)
- • 3. Severe Disability
- • 4. MRI contradictions (index child only)
About New York State Psychiatric Institute
The New York State Psychiatric Institute (NYSPI) is a leading research organization dedicated to advancing the understanding and treatment of mental health disorders. Affiliated with Columbia University, NYSPI integrates clinical research with cutting-edge scientific inquiry to develop innovative therapeutic strategies and improve patient care. With a focus on a wide range of psychiatric conditions, NYSPI conducts clinical trials that aim to translate findings from laboratory research into effective interventions, enhancing the quality of life for individuals affected by mental illness. Committed to ethical research practices and collaboration, NYSPI plays a pivotal role in shaping the future of psychiatric care through rigorous scientific exploration and community engagement.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New York, New York, United States
São Paulo, Sp, Brazil
Patients applied
Trial Officials
Cristiane Duarte, PhD
Principal Investigator
New York State Psychiatric Institute
Andrea Jackowsi, PhD
Principal Investigator
Federal University of São Paulo
Jonathan Posner, MD
Principal Investigator
Duke University
Tenneill Murray, MPH
Study Director
New York State Psychiatric Institute
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials